

Freedom of Information Request: Our Reference CTMUHB_262_22

You asked:

Q1. Does your Health Board treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?

Yes.

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?

15 patients with DLBCL were on treatment during this time frame (some had started before Jan 2022 but ongoing during the audit period).

Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Other immuno-chemotherapy**
- **Other chemotherapy**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only**
- **Tisagenlecleucel**
- **Axicabtagene ciloleucel**
- **Lisocabtagene maraleucel**

We can confirm that the Health Board does hold this information. However, to release the specific information in the way that you have requested would mean disclosure of low numbers.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain.

In our view disclosure of these low figures would breach the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

However, in order to fulfil our obligation under Section 16 of the Act to provide advice and assistance, we can confirm that 8 patients were on the listed treatments.

Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **CAR-T therapy (Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel)**

Please see response to question 3 (Section 40). However, we can confirm that less than 5 patients were referred to other Health Boards.

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

We can confirm that we currently have no open trials for DLBCL.